Conference reports

Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019

INSTI and weight gain: reports from CROI 2019

B/F/TAF suitable for children from six years of age

25th Annual BHIVA Conference (BHIVA 2019)

BHIVA preconference: U=U and HIV and immigration detention

Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports

bNAb research at CROI 2019: vaccine, prevention, treatment and cure…

Paediatric dolutegravir update

Other cure related studies at CROI 2019

Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports

Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10

Capsid inhibitor GS-6207 shows potential for 3-monthly injections

First phase 1 results from bNAb PGT121 in HIV positive people

Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies

Same-day ART is effective in San Francisco Rapid-ART clinic

Integrase inhibitors and neural tube defects: more data still needed

Double-dose levonorgestrel implant does not overcome interaction with efavirenz

Efavirenz and rifampicin together reduce levels of injectable contraception

Bedaquiline and delamanid safe when given together to treat drug resistant TB

Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

Conference on Retroviruses and Opportunistic Infections (CROI 2019): early reports

UK patient likely to be the second person cured of HIV: two further cases at CROI 2019 of HIV remission after allogenic stem cell transplants

Phase 3 results with dual therapy cabotegravir/rilpivirine long-acting injections: ATLAS and FLAIR studies

Viral reservoir can explain persistent low level viraemia with good adherence on ART

Dolutegravir suppresses viral load faster than efavirenz in late pregnancy: results from DolPHIN-2

Raltegravir achieves swifter viral load suppression in pregnancy than efavirenz

New option for PrEP – TAF/FTC is non-inferior to TDF/FTC: results of phase 3 DISCOVER study

Dolutegravir can be given with 3HP to prevent TB without dose adjustment

Double doses of darunavir given with rifampicin lead to high rates of hepatoxicity

Shared housing compared to living alone: higher CD4, lower viral load and reduced inflammation in macaques

Selected webcasts at CROI 2019

i-Base Fit for Purpose report launched at CROI 2019

Pre-CROI Community HIV Cure Workshop 2019

27th International Workshop on HIV Drug Resistance and Treatment Strategies

Drug resistance in low- and middle-income countries

Glasgow HIV Congress (2018) – second reports

Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort

Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood 

3rd HIV Research for Prevention Conference (R4P2018) – second reports

3D printing technology has potential to individualise production of vaginal rings

22nd International AIDS Conference (AIDS 2018) – final report

No significant decrease in raltegravir free fraction during pregnancy

Glasgow HIV Congress (2018)

No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts

Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester

Viral dynamics of dolutegravir-based dual versus triple ART

Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV

Fostemsavir: 48-week phase 3 results from BRIGHTE study

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon  

3rd HIV Research for Prevention Conference (R4P2018)

How to evaluate PrEP and vaccines: urgency for next generation compounds

Dual bNAb maintains viral suppression for median 21 weeks off-ART

Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP

3D imaging show HIV infection might establish within hours

bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges

Why U=U does not cover breastfeeding

BHIVA Autumn Conference 2018

Second case of potential HIV eradication

New UK PrEP guidelines 2018

Other selected talks at BHIVA Autumn 2018

9th International Workshop on HIV and Ageing

Detectable viral load quadruples odds of recurrent falls in older men with HIV

More than 40% of HIV group has hepatic steatosis, regardless of age

Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV – 18% lonely quite often

Physical function worse in older women than men with HIV, despite better CD4 recovery

Post navigation